Tvardi Therapeutics (TVRD) Price & Analysis

Compare

2,493 Followers

TVRD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.10 - $40.77

Previous CloseN/A

VolumeN/A

Average Volume (3M)38.37K

Market Cap

$347.25M

Enterprise Value$156.52M

Total Cash (Recent Filing)$40.99M

Total Debt (Recent Filing)$254.00K

Price to Earnings (P/E)―

Beta1.09

Next Earnings

May 12, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-46.64

Shares Outstanding9,377,433

10 Day Avg. Volume74,969

30 Day Avg. Volume38,368

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.45

Enterprise Value/Revenue23.79

Enterprise Value/Gross Profit24.39

Enterprise Value/Ebitda-5.85

Forecast

1Y Price Target

$60.60

Price Target Upside64.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAn independent monitoring committee opined that the trial should continue as is, strongly hinting that TTI-101 might be achieving meaningful FVC preservation.

Financial OutlookTVRD has $41 million in cash, providing a financial runway into the fourth quarter of 2026, past important phase 2 readouts.

Market PotentialTTI-101 has potential to emerge as a cornerstone therapy in the multi-billion IPF market.

Bears Say

CompetitionThe base case assumes TTI-101 has a profile that is at least superior to BMS' admilparant.

Trial RisksTrial progress appears to be uneventful with no emerging adverse events prompting any disclosure, increasing conviction on REVERTIPF prospects.

Tvardi Therapeutics News

BTIG biotech analyst holds a dinner meeting

Biotech Analyst Harrison holds a dinner meeting with Tvardi Therapeutics (TVRD) to discuss Emerging Trends in Pulmonary Fibrosis...

2d ago

TVRD

3 Best Stocks to Buy Now, 9/11/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

15d ago

CATX

ONON

Nine new option listings and one option delisting on September 10th

New option listings for September 10th include American Bitcoin Corp (ABTC), LightPath (LPTH), Kindly MD Inc (NAKA), Palatin...

16d ago

ABTC

LPTH

Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial Prospects

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TVRD stock, giving a Buy rating on August...

30d ago

TVRD

Tvardi Therapeutics Reports Q2 2025 Financial Results

Tvardi Therapeutics Inc. ( ($TVRD) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

TVRD

Eight option delistings on August 18th

Option delistings effective August 18th include Q32 Bio Inc (QTTB), Hyperdynamics Corp (HYPD), Bionano Genomics (BNGO), Allurion Technologies...

1M ago

ABTS

ALUR

Tvardi Therapeutics Faces Legal and Financial Risks from Exclusive Forum Provision

Tvardi Therapeutics Inc. (TVRD) has disclosed a new risk, in the Share Price & Shareholder Rights category. Tvardi...

1M ago

TVRD

Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, “We are on track for topline data in the...

1M ago

TVRD

Tvardi Therapeutics expects cash to fund operations into Q4 2026

Cash runway anticipated to be sufficient to fund operations into Q4 2026 Published first on TheFly – the...

1M ago

TVRD

Tvardi Therapeutics management to meet with Piper Sandler

Meeting to be held on July 22 in Boston and on July 23 in New York hosted by...

2M ago

TVRD

Tvardi Therapeutics initiated with an Outperform at Raymond James

Raymond James initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $62 price target The company...

2M ago

TVRD

Tvardi Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $52 price target Published first...

3M ago

TVRD

Coinbase, Datadog, Tvardi, CF, Conagra: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($COIN) ), ( ($DDOG) ), ( ($TVRD) ), ( ($CF)...

3M ago

CAG

Tvardi Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi initiated coverage of Tvardi Therapeutics (TVRD) with an Overweight rating and $78 price...

4M ago

TVRD

TVRD FAQ

What was Tvardi Therapeutics’s price range in the past 12 months?

Tvardi Therapeutics lowest stock price was $8.10 and its highest was $40.77 in the past 12 months.

What is Tvardi Therapeutics’s market cap?

Tvardi Therapeutics’s market cap is $347.25M.

When is Tvardi Therapeutics’s upcoming earnings report date?

Tvardi Therapeutics’s upcoming earnings report date is May 12, 2025 which is 137 days ago.

How were Tvardi Therapeutics’s earnings last quarter?

Currently, no data Available

Is Tvardi Therapeutics overvalued?

According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tvardi Therapeutics pay dividends?

Tvardi Therapeutics does not currently pay dividends.

What is Tvardi Therapeutics’s EPS estimate?

Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tvardi Therapeutics have?

Tvardi Therapeutics has 9,377,433 shares outstanding.

What happened to Tvardi Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tvardi Therapeutics?

Currently, no hedge funds are holding shares in TVRD

Tvardi Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-93.85%

Trailing 12-Months

Asset Growth

-39.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tvardi Therapeutics

Tvardi Therapeutics (TVRD) is a biotechnology company focused on the development of innovative therapeutic solutions for cancer and other serious diseases. The company specializes in the discovery and advancement of small molecule drugs aimed at targeting specific pathways involved in disease progression. Tvardi's core product pipeline includes novel compounds that are designed to inhibit key proteins, thereby offering potential new treatments for various types of cancer and other conditions.

Tvardi Therapeutics (TVRD) Earnings & Revenues

Historic Earnings Reports

TVRD Stock 12 Month Forecast

Average Price Target

$60.60

▲(64.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","44":"$44","79":"$79","26.5":"$26.5","61.5":"$61.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,26.5,44,61.5,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,33.30461538461538,37.029230769230765,40.753846153846155,44.47846153846154,48.20307692307692,51.92769230769231,55.652307692307694,59.37692307692308,63.10153846153846,66.82615384615384,70.55076923076923,74.27538461538461,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,31.966153846153844,34.35230769230769,36.738461538461536,39.12461538461538,41.51076923076923,43.89692307692307,46.28307692307692,48.669230769230765,51.05538461538461,53.44153846153846,55.8276923076923,58.213846153846156,{"y":60.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.58,30.84307692307692,32.106153846153845,33.36923076923077,34.63230769230769,35.895384615384614,37.15846153846154,38.42153846153846,39.684615384615384,40.94769230769231,42.21076923076923,43.473846153846154,44.73692307692308,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.31,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.38,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.47,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.36,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.34,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.76,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >